Barinthus Biotherapeutics (BRNS) Accumulated Depreciation & Amortization (2020 - 2025)
Barinthus Biotherapeutics (BRNS) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $5.8 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 6.83% year-over-year to $5.8 million, compared with a TTM value of $5.8 million through Dec 2024, up 6.83%, and an annual FY2024 reading of $5.8 million, up 6.83% over the prior year.
- Accumulated Depreciation & Amortization was $5.8 million for Q4 2024 at Barinthus Biotherapeutics, up from $5.4 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $5.8 million in Q4 2024 and bottomed at $479000.0 in Q4 2020.
- Average Accumulated Depreciation & Amortization over 5 years is $3.4 million, with a median of $4.3 million recorded in 2022.
- The sharpest move saw Accumulated Depreciation & Amortization surged 387.92% in 2022, then rose 6.83% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $479000.0 in 2020, then surged by 84.97% to $886000.0 in 2021, then soared by 387.92% to $4.3 million in 2022, then increased by 25.58% to $5.4 million in 2023, then rose by 6.83% to $5.8 million in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for BRNS at $5.8 million in Q4 2024, $5.4 million in Q4 2023, and $4.3 million in Q4 2022.